About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ALNY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and…
NCT07575308 · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
ALN-6400
ALNY
Alnylam Pharmaceuticals
Phase 2Recruiting24Jun 30, 2027Registry ↗
Nov 13, 2026A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT07465224 · Type 2 Diabetes Mellitus (T2DM)
ALN-4324, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 2Active, not recruiting
was recruiting
24May 28, 2027Registry ↗
Nov 13, 2026A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
NCT07295717 · Healthy Volunteers
ALN-4285, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting76Dec 29, 2026Registry ↗
Nov 13, 2026A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712 · Cerebral Amyloid Angiopathy
Placebo, ALN-APP
ALNY
Alnylam Pharmaceuticals
Phase 2Active, not recruiting210Aug 9, 2027Registry ↗
Nov 12, 2026A Study to Evaluate ALN-6222 in Participants With Obesity
NCT07624071 · Obesity
ALN-6222, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting88Dec 14, 2027Registry ↗
Nov 12, 2026A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated W…
NCT07553442 · Hypertension
ALN-AGT01 RVR, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 2Recruiting93Apr 1, 2028Registry ↗
Nov 12, 2026A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
NCT07535606 · Healthy Volunteers
ALN-4915, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Active, not recruiting36Jul 31, 2027Registry ↗
Nov 12, 2026A Study to Evaluate ALN-2232 in Participants With Obesity
NCT07463846 · Obesity
ALN-2232, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Recruiting156Apr 28, 2027Registry ↗
Nov 12, 2026Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Car…
NCT07181109 · High Risk Cardiovascular Disease, Hypertension
Zilebesiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 3Recruiting11,000Sep 23, 2030Registry ↗
Nov 12, 2026A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785 · Early-Onset Alzheimer Disease
ALN-APP, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting60Jan 11, 2029Registry ↗
Nov 2, 2026HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyop…
NCT04153149 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Vutrisiran, Sterile Normal Saline (0.9% NaCl)
ALNY
Alnylam Pharmaceuticals
Phase 3Active, not recruiting655May 8, 2024Registry ↗
Oct 27, 2026A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellula…
ALN-BCAT, Pembrolizumab
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting158Sep 30, 2027Registry ↗
Oct 21, 2026A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Vutrisiran
ALNY
Alnylam Pharmaceuticals
Phase 3Enrolling by invitation700Mar 31, 2028Registry ↗
Oct 20, 2026TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyo…
NCT07052903 · Transthyretin Amyloidosis With Cardiomyopathy
Nucresiran, Sterile Normal Saline (0.9% NaCl)
ALNY
Alnylam Pharmaceuticals
Phase 3Recruiting1,750May 28, 2030Registry ↗
Oct 20, 2026A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese P…
NCT06845202 · Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mel…
ALN-4324, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Active, not recruiting105Aug 31, 2027Registry ↗
Oct 15, 2026A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangi…
NCT06659640 · Hereditary Hemorrhagic Telangiectasia
ALN-6400, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Active, not recruiting89Jan 5, 2028Registry ↗
Oct 15, 2026A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449 · Huntington's Disease
ALN-HTT02, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting66Jul 5, 2028Registry ↗
Oct 15, 2026Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of t…
NCT06360289 · Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic…
Standard of Care
ALNY
Alnylam Pharmaceuticals
—Active, not recruiting346Dec 15, 2027Registry ↗
Oct 13, 2026A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzh…
NCT07636811 · Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Mivelsiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 2Recruiting58May 18, 2030Registry ↗
Oct 13, 2026ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis…
NCT04561518 · Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
ALNY
Alnylam Pharmaceuticals
—Recruiting1,500Dec 31, 2033Registry ↗
Oct 9, 2026DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a R…
NCT07358078 · Transthyretin Amyloidosis With Cardiomyopathy
ALNY
Alnylam Pharmaceuticals
—Recruiting2,000Oct 23, 2030Registry ↗
Oct 8, 2026TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Tr…
NCT07223203 · Hereditary Transthyretin-Mediated Amyloidosis With Polyneur…
Nucresiran, Vutrisiran
ALNY
Alnylam Pharmaceuticals
Phase 3Recruiting125Dec 27, 2027Registry ↗
Oct 8, 2026A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727 · Alzheimer's Disease
ALN-5288, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Recruiting50Mar 6, 2030Registry ↗
Oct 8, 2026Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT05040373 · Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Poly…
ALNY
Alnylam Pharmaceuticals
—Recruiting10Oct 12, 2030Registry ↗
Oct 6, 2026BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393 · Primary Hyperoxaluria Type 1
ALNY
Alnylam Pharmaceuticals
—Active, not recruiting207Jan 2, 2029Registry ↗
Oct 6, 2026ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905 · Acute Hepatic Porphyria
ALNY
Alnylam Pharmaceuticals
—Recruiting150Dec 31, 2030Registry ↗
Apr 30, 2026A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
NCT06423352 · Mild to Moderate Hypertension
Zilebesiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Completed36Jul 17, 2025Registry ↗
Apr 20, 2026APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiom…
NCT03997383 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Placebo, Patisiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed360Jun 20, 2022Registry ↗
Mar 2, 2026Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequa…
NCT06272487 · High Cardiovascular Risk, Hypertension
Zilebesiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 2Completed375Jun 19, 2025Registry ↗
Feb 17, 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04…
NCT05661916 · Transthyretin-Mediated Amyloidosis
ALN-TTRSC04, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Completed96Sep 30, 2025Registry ↗
Jan 12, 2026HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis…
NCT03759379 · Amyloidosis, Hereditary, Transthyretin Amyloidosis
Patisiran, Vutrisiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed164Nov 10, 2020Registry ↗
Dec 23, 2025A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
NCT04936035 · Hypertension
Placebo, ALN-AGT01
ALNY
Alnylam Pharmaceuticals
Phase 2Completed394Apr 4, 2023Registry ↗
Nov 3, 2025Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard…
NCT05103332 · Hypertension
Indapamide, Amlodipine
ALNY
Alnylam Pharmaceuticals
Phase 2Completed663Dec 11, 2023Registry ↗
Sep 19, 2025A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers
NCT06675565 · Healthy Volunteers
ALN-AGT01 RVR, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Completed42Sep 8, 2025Registry ↗
Jul 18, 2025A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
NCT04152200 · Primary Hyperoxaluria Type 1, Primary Hyperoxaluria
Lumasiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed21May 18, 2021Registry ↗
May 7, 2025A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients…
NCT05761301 · Type 2 Diabetes Mellitus (T2DM)
ALN-KHK, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Terminated49Apr 3, 2025Registry ↗
Feb 14, 2025A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
NCT03905694 · Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)
Lumasiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed18Jun 29, 2020Registry ↗
Aug 12, 2024A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
NCT03681184 · Primary Hyperoxaluria Type 1 (PH1)
Placebo, Lumasiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed39Nov 5, 2019Registry ↗
Aug 9, 2024A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT03841448 · IgA Nephropathy (IgAN), Berger Disease
Placebo, Cemdisiran
ALNY
Alnylam Pharmaceuticals
Phase 2Terminated31Mar 17, 2022Registry ↗
May 22, 2024A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Ele…
NCT05161936 · Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Ur…
Lumasiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 2Terminated2Nov 1, 2022Registry ↗
May 20, 2024Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
NCT04056481 · Acute Hepatic Porphyria
Givosiran
ALNY
Alnylam Pharmaceuticals
—Approved for marketing——Registry ↗
May 20, 2024Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
NCT02939820 · TTR-mediated Amyloidosis, Amyloidosis, Hereditary
patisiran (ALN-TTR02)
ALNY
Alnylam Pharmaceuticals
—Approved for marketing——Registry ↗
May 17, 2024A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (…
NCT04565717 · Nonalcoholic Steatohepatitis, NASH
ALN-HSD, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1Terminated6Jan 6, 2023Registry ↗
Apr 25, 2024An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hy…
NCT03350451 · PH1, Primary Hyperoxaluria
Lumasiran
ALNY
Alnylam Pharmaceuticals
Phase 2Completed20Feb 7, 2023Registry ↗
Apr 22, 2024Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Diseas…
NCT03862807 · Amyloidosis, Familial, Transthyretin Amyloidosis
Patisiran
ALNY
Alnylam Pharmaceuticals
Phase 3Completed24Oct 6, 2020Registry ↗
Apr 22, 2024ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute…
NCT03338816 · Acute Hepatic Porphyria, Acute Intermittent Porphyria
Givosiran, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 3Completed94Jan 31, 2019Registry ↗
Apr 22, 2024APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyr…
NCT01960348 · TTR-mediated Amyloidosis, Amyloidosis, Hereditary
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
ALNY
Alnylam Pharmaceuticals
Phase 3Completed225Aug 2017Registry ↗
Apr 19, 2024The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in…
NCT01961921 · TTR-mediated Amyloidosis
ALN-TTR02 (patisiran) administered by intravenous (IV) infu…
ALNY
Alnylam Pharmaceuticals
Phase 2Completed27Jul 2016Registry ↗
Apr 19, 2024Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
NCT01617967 · TTR-mediated Amyloidosis
Patisiran
ALNY
Alnylam Pharmaceuticals
Phase 2Completed29Oct 2013Registry ↗
Mar 29, 2024A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
NCT05256810 · Gout
ALN-XDH, Placebo
ALNY
Alnylam Pharmaceuticals
Phase 1/2Terminated44Jan 25, 2023Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:06 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances